Abstract
A series of 5,7-dihydroxyflavanone derivatives were efficiently synthesized. Their antimicrobial efficacy on Gram-negative, Gram-positive bacteria and yeast were evaluated. Among these compounds, most of the halogenated derivatives exhibited the best antimicrobial activity against Gram-positive bacteria, the yeast Saccharomyces cerevisiae, and the Gram-negative bacterium Vibrio cholerae. The cytotoxicities of these compounds were low as evaluated on HepG2 cells using a cell viability assay. This study suggests that halogenated flavanones might represent promising pharmacological candidates for further drug development.
Keywords: Synthesis, Halogenated flavanones, Antimicrobial activity, Cytotoxicity
Flavanones are an important class of flavonoids containing a 2-phenyl-benzopyran-4-one skeleton, and are commonly found in fruits and vegetables.1–3 These natural products possess a variety of biological activities such as antitumor and anti-inflammatory properties that are closely related to the skeleton and substitution patterns.2–7 The ability to manipulate flavonoid activity through structural variation motivates research on the synthesis of flavanone derivatives and evaluation of their bioactivity.8–16
Pinocembrin (5,7-dihydroxyflavanone) 1, is one of the primary flavanones which is abundant in propolis and can be extracted from plants, fruits, vegetables, seeds, flowers and teas (Fig. 1).17 A vast range of biological/pharmacological activities for pinocembrin have been reported, including antimicrobial, anti-inflammatory, anticancer and antioxidant, as well as neuroprotective potential.17,18 Pinocembrin is a small molecular weight natural compound and is a biologically active constituent of honey. Its presence in food suggests its safety for long-term administration, making it an excellent chemical template for the design and synthesis of new compounds for pharmaceutical research. Recently, we reported the antimicrobial efficacy of synthetic flavanone derivatives.19 Derivatives were identified that impede growth of a series of organisms. For instance, 4-chloro-flavanone, when combined with the inhibitor Phe-Arg-β-naphthylamide, exhibits MIC’s of 30, 30 and 70 μg mL−1 for Saccharomyces cerevisiae, Cryptococcus neoformans and Escherichia coli, respectively.19 These results led us to hypothesize that halide substitution of flavanones might show enhanced antimicrobial activity. In addition, there is increased interest in bioactive halogenated compounds.20–23 Here, we use an improved synthetic approach to obtain a series of mostly halogenated 5,7-dihydroxyflavanone derivatives that were assessed for antimicrobial efficacy and mammalian cytotoxicity.
Figure 1.

Chemical structure of Pinocembrin (1).
A modified synthetic approach was developed based on a conventional route to efficiently obtain a small library of flavanones.24 Synthesis commenced with partial methoxymethyl (MOM) protection of 2,4,6-trihydroxy acetophenone monohydrate to produce phenol 10 (Scheme 1). A series of substituted benzaldehydes were reacted with phenol 10, through a Claisen–Schmidt condensation, to prepare a series of chalcone intermediates 11 with different substituents on their B-ring. The corresponding chalcones 11 were cyclized with sodium acetate to provide the protected flavanones 12. Finally, acidic hydrolysis of the MOM groups afforded the flavanone derivatives 2–8 (Table 1). Compared to the conventional synthetic method, the efficiency of this synthesis is demonstrated by only one column chromatography step being required for the conversion of phenol 10 to the target flavanones 2–8. The structures of flavanone derivatives 2–8 were confirmed from their spectral (1H- and 13C-nuclear magnetic resonance (NMR) and high resolution-mass spectrometry (MS)) properties (see the Supplementary data).
Scheme 1.

Reagents and conditions: (a) Methoxymethyl (MOM) chloride, N,N-diisopropylethylamine, DCM, 0 °C, 12 h, 95%; (b) KOH, substituted benzaldehyde, MeOH, 16 h; (c) NaOAc, MeOH, reflux, 24 h; (d) 6 N HCl, MeOH, 60 °C, 42–56% yield over 3-steps.
Table 1.
Target compounds
| Compd | R1 | R2 | R3 | Yielda (%) |
|---|---|---|---|---|
| 225 | H | F | H | 45 |
| 3 | F | F | H | 56 |
| 4 | F | F | F | 52 |
| 5 | F | Cl | H | 45 |
| 626 | Cl | Cl | H | 47 |
| 7 | OH | OH | OH | 42 |
| 827 | H | MeO | H | 45 |
Isolated yield from compound 10 over 3 steps.
The antimicrobial activities of 5,7-dihydroxyflavanone derivatives 2–8 were evaluated by measuring their inhibitory effect against a series of Gram-negative and Gram-positive bacteria and yeast and their minimum inhibitory concentration (MIC) values were determined.
Natural flavanones as bacteriostatic agents have been investigated in the past, and have shown no inhibition against E. coli,19 which is a Gram-negative bacterium. However, natural flavanones did show inhibition against Bacillus subtilis,19 which is a Gram-positive organism. Normally, compounds show greater potency against Gram-positive than Gram-negative bacteria, since the Gram-negative bacteria have both an outer and an inner membrane making the cell permeability of an antimicrobial agent much more difficult.
Results herein are consistent with a previous report on the antimicrobial activity of natural flavanones.19 Non-natural flavanones 2–8 were ineffective at inhibiting growth of the Gram-negative bacteria E. coli and Pseudomonas aeruginosa (Table 2).
Table 2.
Non-natural flavanone MIC values in μg mL−1(μM)
| Organism | Compounds |
||||||
|---|---|---|---|---|---|---|---|
| 2 | 3 | 4 | 5 | 6 | 7 | 8 | |
| Gram-negative bacteria | |||||||
| Escherichia coli BW25113 | >140a(500)b | >290(1000) | >310(1000) | >80(250) | >40(125) | >300(1000) | >290(1000) |
| Pseudomonas aeruginosa PA01 | >140(500) | >290(1000) | >310(1000) | >80(250) | >40(125) | >300(1000) | >290(1000) |
| Vibrio cholerae0395N1 | 30(125) | 40(125) | >310(1000) | 40(125) | 40(125) | >300(1000) | >290(1000) |
| Gram-positive bacteria | |||||||
| Bacillus subtilis 1012 | 30(125) | 40(125) | >310(1000) | 40(125) | 20(62.5) | >300(1000) | >290(1000) |
| Bacillus anthracis delta sterne | 30(125) | 20(62.5) | >310(1000) | 20(62.5) | 10(31.25) | >300(1000) | >290(1000) |
| Bacillus cereus 10987 | 30(125) | 40(125) | >310(1000) | 30(93.75) | 10(31.25) | >300(1000) | >290(1000) |
| Staphylococcus aureus ATCC 33807 | 30(125) | 40(125) | >310(1000) | 40(125) | 20(62.5) | >300(1000) | >290(1000) |
| Eukaryote | |||||||
| Saccharomyces cerevisiae INVSc1 | 60(250) | >290(1000) | 40(125) | 80(250) | 10(31.25) | >300(1000) | >290(1000) |
Concentration unit is μg mL−1.
Concentration unit is μM.
However, halogenated derivatives 2, 3, 5 and 6 showed significant activities (30–40 μg mL−1) against Vibrio cholera, a Gram-negative organism. To the best of our knowledge, this is one of the rare examples of the inhibition of Gram-negative bacteria by flavanones.
Next, the activity of flavanones 2–8 was tested against the following Gram-positive bacteria: Bacillus subtilis 1012, Bacillus anthracis, Bacillus cereus 10987 and Staphylococcusaureus ATCC 33807. The lowest MIC values observed were obtained for the flavanones 2, 5 and 6, which contain halide substituents. The dichlorinated flavanone 6 provided the greatest inhibition of the growth of all the Gram-positive strains tested, exhibiting MIC values ranging from 10 to 20 μg mL−1. Flavanones without halogen substituents did not inhibit the growth of Gram-positive strains, and not all flavanones having halogens inhibited microbial growth. For example, the trifluorinated flavanone 4 had no effect on growth for Gram-positive bacteria, while the monofluorinated and difluorinated flavanone, 2 and 3, afforded low MIC values. Inhibition of microbial growth was observed for trifluorinated compound 4 when tested against S. cerevisiae, affording a MIC of 40 μg mL−1. Most importantly, the MIC values for some of the flavanones tested were better than that of their natural analogs, approaching MIC values observed for traditional antibiotics. All of the antimicrobial results were confirmed in triplicate using a 96-well plates bioassay.
We next used a MTS (5-(3-carboxymethoxyphenyl)-2-(4,5-dimethylthiazoly)-3-(4-sulfophenyl) tetrazolium inner salt) cell viability assay to evaluate mammalian cytotoxicity of 5,7-Dihydroxyflavanone derivatives in HepG2 cells. HepG2 is a well-established human hepatocellular carcinoma cell line. Approximately 50,000 cells were seeded and incubated for 24 h before addition of 5,7-dihydroxyflavanone to samples and to the controls. MTS reagent was added at 6 and 24 h of incubation and cell viability was determined by measuring Abs490. The poor water solubility of many flavanones limited the range of concentrations that could be evaluated. The 5,7-dihydroxyflavanone derivatives generally had low water solubility, ranging from 50 to 2000 μM in growth medium containing 1% dimethylsulfoxide (DMSO). The maximal solubility for compounds 6 and 7 was 63 μM, for compounds 4 and 5 was 500 μM, and for compound 2 and 3, 1000 μM. Methoxy-flavanone 8 had the highest solubility at 2000 μM. All of the flavanones showed dose-dependent toxicity towards HepG2 cells. Because of the limited solubility of the flavanones, it was only possible to obtain an IC50 value for compound 4 of 95 μM after 24 h. At a concentration of 50 μM (14–16 μg mL−1), all the derivatives were completely soluble and exhibited low to no cytotoxicity towards HepG2 cells (Fig. 2). At this concentration, the order of their relative cytotoxicity to HepG2 cells is as follows: compound 4 > compound 3 > compound 2 > compound 5 > compound 8 > compound 7 > compound 6. Toxicity increased with greater number of fluorine substituents, while OMe, OH, and Cl substituents promoted the proliferation of HepG2 cells. The dichlorinated flavanone 6 which has the highest antibacterial activity against all of the microorganisms tested, showed the lowest level of cytotoxicity and promoted proliferation of HepG2 cells by 17% at 6 h, and 57% at 24 h over that obtained in cell culture growth medium.
Figure 2.

Cytotoxicity of 5,7-dihydroxyflavanone derivatives on HepG2 cells. Cell viability was measured after incubating HepG2 cells with 50 μM of flavanone derivative by MTS assay. Cell viability was normalized based on the negative control (100% growth medium) and positive control (100% DMSO). Flavonone 3 shows least toxicity out of the compounds that were tested. Open bars correspond to 24 h and closed bars correspond to 6 h. A single experiment was performed with three replicate determinations. The error bars included in the figure are too small to be seen.
In summary, a series of 5,7-dihydroxyflavanone derivatives 2–8 were designed and efficiently synthesized. Their antimicrobial activity on Gram-negative, Gram-positive bacteria and yeast were evaluated as well as their cytotoxicity in HepG2 cells. In this study, most of the halogenated compounds showed greater antimicrobial activity (lower MIC values) than their natural analogs. Further discovery through target design and synthesis, as well as mechanistic studies are underway.
Supplementary Material
Footnotes
Supplementary data
Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.bmcl.2016.05.003.
References and notes
- 1.Pandey RP; Parajuli P; Koffas MAG; Sohng JK Biotechnol. Adv 2016. 10.1016/j.biotechadv.2016.02.012. [DOI] [PubMed] [Google Scholar]
- 2.Verma AK; Pratap R Tetrahedron 2012, 68, 8523. [Google Scholar]
- 3.Singh M; Kaur M; Silakari O Eur. J. Med. Chem 2014, 84, 206. [DOI] [PubMed] [Google Scholar]
- 4.Havsteen B Biochem. Pharmacol 1983, 32, 1141. [DOI] [PubMed] [Google Scholar]
- 5.Silberberg M; Gil-Izquierdo A; Combaret L; Remesy C; Scalbert A; Morand C Biomed. Pharmacother 2006, 60, 529. [DOI] [PubMed] [Google Scholar]
- 6.Trantas EA; Koffas M; Xu P; Ververidis F Front. Plant Sci 2015, 6, 7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Wang J; Guleria S; Koffas MAG; Yan Y Curr. Opin. Biotech 2016, 37, 97. [DOI] [PubMed] [Google Scholar]
- 8.Xiao Z-P; Peng Z-Y; Dong J-J; He J; Ouyang H; Feng Y-T; Lu C-L; Lin W-Q; Wang J-X; Xiang Y-P; Zhu H-L Eur. J. Med. Chem 2013, 63, 685. [DOI] [PubMed] [Google Scholar]
- 9.Shi L; Feng XE; Cui JR; Fang LH;Du GH;Li QS Bioorg. Med. Chem. Lett 2010, 20, 5466. [DOI] [PubMed] [Google Scholar]
- 10.Pandurangan N; Bose C; Banerji A Bioorg. Med. Chem. Lett 2011, 21, 5328. [DOI] [PubMed] [Google Scholar]
- 11.Mavel S; Dikic B; Palakas S; Emond P; Greguric I; de Gracia AG; Mattner F; Garrigos M; Guilloteau D; Katsifis A Bioorg. Med. Chem 2006, 14, 1599. [DOI] [PubMed] [Google Scholar]
- 12.Bhan N; Cress BF; Linhardt RJ; Koffas MAG Biochimie 2015, 115, 136. [DOI] [PubMed] [Google Scholar]
- 13.Bhan N; Li L; Cai C; Xu P; Linhardt RJ; Koffas MAG Protein Sci. 2015, 24, 167. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Mora-Pale M; Sanchez-Rodriguez SP; Linhardt RJ; Dordick JS; Koffas MAG. Curr. Opin. Biotech 2014, 25, 86. [DOI] [PubMed] [Google Scholar]
- 15.Chemler JA; Lim CG; Daiss JL; Koffas MAG Chem. Biol 2010, 17, 392. [DOI] [PubMed] [Google Scholar]
- 16.Chemler JA; Yan Y; Leonard E; Koffas MAG Org. Lett 1855, 2007, 9. [DOI] [PubMed] [Google Scholar]
- 17.Rasul A; Millimouno FM; Ali Eltayb W; Ali M; Li J; Li X BioMed. Res. Int 2013, 2013, 9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Liu R; Li J-Z; Song J-K; Zhou D; Huang C; Bai X-Y; Xie T; Zhang X; Li Y-J; Wu C-X; Zhang L; Li L; Zhang T-T; Du G-H Neurobiol. Aging 2014, 35, 1275. [DOI] [PubMed] [Google Scholar]
- 19.Fowler ZL; Shah K; Panepinto JC;Jacobs A; Koffas MAG PLoS One 2011, 6 e25681. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Yaipakdee P; Robertson LW Phytochemistry 2001, 57, 341. [DOI] [PubMed] [Google Scholar]
- 21.Blunt JW; Copp BR; Hu W-P; Munro MHG; Northcote PT; Prinsep MR Nat. Prod. Rep 2009, 26, 170. [DOI] [PubMed] [Google Scholar]
- 22.Paul C; Pohnert G Nat. Prod. Rep 2011, 28, 186. [DOI] [PubMed] [Google Scholar]
- 23.Huang H; Wang F; Luo M; Chen Y; Song Y; Zhang W; Zhang S; Ju J J. Nat. Prod 2012, 75, 1346. [DOI] [PubMed] [Google Scholar]
- 24.Urgaonkar S; La Pierre HS; Meir I; Lund H; RayChaudhuri D; Shaw JT Org. Lett 2005, 7, 5609. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Katsuyama Y; Funa N; Miyahisa I; Horinouchi S Chem. Biol 2007, 14, 613. [DOI] [PubMed] [Google Scholar]
- 26.Chang L-S; Li C-B; Qin N; Jin M-N; Duan H-Q Chem. Biodivers 2012, 9, 162. [DOI] [PubMed] [Google Scholar]
- 27.Sun L-P; Ma W-P; Gao L-X; Yang L-L; Quan Y-C; Li J; Piao H-R J. Enzym. Inhib. Med. Chem 2013, 28, 1199. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
